GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Debt-to-Revenue

AEterna Zentaris (AEterna Zentaris) Debt-to-Revenue : 0.19 (As of Mar. 2024)


View and export this data going back to 1992. Start your Free Trial

What is AEterna Zentaris Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

AEterna Zentaris's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.30 Mil. AEterna Zentaris's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.29 Mil. AEterna Zentaris's annualized Revenue for the quarter that ended in Mar. 2024 was $8.20 Mil. AEterna Zentaris's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.19.


AEterna Zentaris Debt-to-Revenue Historical Data

The historical data trend for AEterna Zentaris's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Debt-to-Revenue Chart

AEterna Zentaris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.20 0.15 0.14 0.23

AEterna Zentaris Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.33 0.22 0.34 0.19

Competitive Comparison of AEterna Zentaris's Debt-to-Revenue

For the Biotechnology subindustry, AEterna Zentaris's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AEterna Zentaris's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Debt-to-Revenue falls into.



AEterna Zentaris Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

AEterna Zentaris's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.295 + 1.38) / 7.18
=0.23

AEterna Zentaris's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.296 + 1.293) / 8.196
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


AEterna Zentaris Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


AEterna Zentaris (AEterna Zentaris) Business Description

Traded in Other Exchanges
Address
7824-51 Avenue NW, Edmonton, AB, CAN, T6E 6W2
Ceapro Inc is engaged in the development and marketing of various health and wellness products and technology relating to plant extracts. Its operating segment is the active ingredient product technology industry which involves the development of proprietary extraction technologies and the application of these technologies to the production and development and commercialization of active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. Active ingredients produced include oat beta glucan and avenanthramides. The group derives revenue from the U.S., Germany, China, Canada and other countries, of which prime revenue is generated from the U.S.